• 1
    Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contribute to androgen-independent progression. Nat Med 1998; 4: 507.
  • 2
    Usmani BA, Harden B, Maitland N J, Turner AJ. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin Sci 2002; 103 ( Suppl 48): 314S7S.
  • 3
    Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 1997; 11: 35564.
  • 4
    Gee NS, Matsas R, Kenny AJ. A monoclonal antibody to kidney endopeptidase-24.11. Its application in immunoadsorbent purification of the enzyme and immunofluorescent microscopy of kidney and intestine. Biochem J 1983; 214: 37786.
  • 5
    Matsas R, Kenny AJ, Turner AJ. An immunohistochemical study of endopeptidase-24.11 ("enkephalinase") in the pig nervous system. Neurosci 1986; 18: 9911012.
  • 6
    Broccolini A, Gidaro T, Morosetti R, Gliubizzi C, Servidei T, Pescatori M, Tonali PA, Ricci E, Mirabella M. Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis. J Neurochem 2006; 96: 77789.
  • 7
    Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res 1996; 56: 8319.
  • 8
    Albrecht M, Gillen S, Wilhelm B, Doroszewicz J, Aumuller G. Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer. J Urol 2002; 168: 33642.
  • 9
    Sumitomo M, Shen R, Nanus DM. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta 2005; 1751: 529.
  • 10
    Hong Y, Macnab S, Lambert LA, Turner AJ, Whitehouse A, Usmani BA. Herpesvirus saimiri (HVS)-based endothelin converting enzyme-1 (ECE-1) shRNA expression decreases prostate cancer cell invasiion and migration. Int J Cancer, in press.
  • 11
    Horiguchi A, Zheng R, Goodman JrOB, Shen R, Guan H, Hersh LB, Nanus DM. Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth. Cancer Gene Ther 2007; 14: 5839.
  • 12
    Shen R, Sumitomo M, Dai J, Hardy DO, Navarro D, Usmani B, Papandreou CN, Hersh LB, Shipp MA, Freedman LP, Nanus DM. Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Mol Cell Endocrinol 2000; 170: 13142.
  • 13
    Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson WG, Nelson JB, Nanus DM. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000; 6: 166470.
  • 14
    Matsas R, Fulcher IS, Kenny AJ, Turner AJ. Substance P and [Leu]enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli. Proc Natl Acad Sci USA 1983; 80: 31115.
  • 15
    Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2008; 5: 21224.
  • 16
    El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Neurobiology 2008; 172: 134254.
  • 17
    Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Costa CA, Vincent B, Ring S, D'Adamio L, Shen J, Muller U, Hyslop PS, Checler F. Presenilin-dependent transcriptional control of the Aβ-degrading enzyme Neprilysin by intracellular domains of βAPP and APLP. Neuron 2005; 46: 54154.
  • 18
    Pardossi-Piquard R, Dunys J, Yu G, St George-Hyslop P, Alves da Costa C, Checler F. Neprilysin activity and expression are controlled by nicastrin. J Neurochem 2006; 97: 10526.
  • 19
    Goodger ZV, Rajendran L, Trutzel A, Kohli BM, Nitsch RM, Konietzko U. Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J Cell Sci 2009; 122: 370314.
  • 20
    Kimberly WT, Zheng JB, Guenette S, Selkoe DJ. The intracellular domain of the β-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in Notch-like manner. J Biol Chem 2001; 276: 4028892.
  • 21
    Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep 2009; 10: 94100.
  • 22
    Nalivaeva NN, Belyaev ND, Turner AJ. Sodium valproate: an old drug with new roles. Trends Pharmacol Sci 2009; 30: 50914.
  • 23
    Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, Nam SW. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005; 113: 2648.
  • 24
    Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004; 59: 17789.
  • 25
    Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 2007; 14: 83945.
  • 26
    Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, Berthe ML, Noel D, Pillon A, Iborra F, Dubus P, Maudelonde T, Culine S, Fajas L. Peroxisome proliferation-activated receptor gamma regualtes E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 2006; 26: 756174.
  • 27
    Belyaev ND, Kellett KA, Beckett C, Makova NZ, Revett TJ, Nalivaeva NN, Hooper NM, Turner AJ. The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway. J Biol Chem 2010; 285: 4144354.
  • 28
    Konietzko U, Goodger ZV, Meyer M, Kohli BM, Bosset J, Lahiri DK, Nitsch RM. Co-localization of the amyloid precurosr protein and Notch intracellular domains in nuclear transcription factories. Neurobiol Aging 2010; 10: 5873.
  • 29
    Nan X, Ng HH, Johnson Ca, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 3869.
  • 30
    Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T. DNMT3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 2001; 20: 253644.
  • 31
    Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol 2003; 5: 4868.
  • 32
    Edbauer D, Willem M, Lammich S, Steiner H, Haass C. Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD). J Biol Chem 2002; 277: 1338993.
  • 33
    Nunan J, Shearman MS, Checler F, Cappai R, Evin G, Beyreuther K, Masters CL, Small DH. The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase. Eur J Biochem 2001; 268: 532936.
  • 34
    McLendon C, Xin T, Ziani-Cherif C, Murphy MP, Findlay KA, Lewis PA, Pinnix I, Sambamurti K, Wang R, Faug A, Golde TE. Cell-free assays for gamma-secretase activity. FASEB J 2000; 14: 23836.
  • 35
    Muller T, Meyer HE, Eqensperger R, Marcus K. The amyloid precurosr protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog Neurobiol 2008; 85: 393406.
  • 36
    Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 2002; 8: 12632.
  • 37
    Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 2002; 110: 5567.
  • 38
    Alves da Costa C, Sunyach C, Pardossi-Piquard R, Sévalle J, Vincent B, Boyer N, Kawarai T, Girardot N, St George-Hyslop P, Checler F. Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci 2006; 26: 637785.
  • 39
    Checler F, Sunyach C, Pardossi-Piquard R, Sevalle J, Vincent B, Kawarai T, Girardot N, St George-Hyslop P, da Costa CA. The gamma/epsilon-secretase-derived APP intracellular domain fragments regulate p53. Curr Alzheimer Res 2007; 4: 4236.
  • 40
    Huysseune S, Kienlen-Campard P, Hebert S, Tasiaux B, Leroy K, Devuyst O, Brion JP, De Strooper B, Octave JN. Epigenetic control of aquaporin 1 expression by the amyloid precursor protein. FASEB J 2009; 23: 415867.
  • 41
    Hebert SS, Serneels L, Tolia A, Craessaerts K, Derks C, Filippov MA, Muller U, De Strooper B. Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. EMBO Rep 2006; 7: 73945.
  • 42
    Chen AC, Selkoe DJ. Response to: Pardossi-Piquard et al., “Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domain of betaAPP and APLP.” Neuron 2007; 46: 54154.
  • 43
    Pardossi-Piquard R, Dunys J, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, Sevalle J, Pimplikar S, St George-Hyslop P, Checler F. Response to correspondance: Pardossi-Piquard et al., “Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domain of betaAPP and APLP.” Neuron 46, 541–554. Neuron 2007; 53: 4836.
  • 44
    Waldron E, Isbert S, Kern A, Jaeger S, Martin AM, Hebert SS, Behl C, Weggen S, De Strooper B, Pietrzik CU. Increased AICD generation does not result in increased nuclear translocation or activation of target gene transcription. Exp Cell Res 2008; 314: 241933.
  • 45
    Takayama K, Tsutsumi S, Suzuki T, Horie-Inoue K, Ikeda K, Kaneshiro K, Fujimura T, Kumagai J, Urano T, Sakaki Y, Shirahige K, Sasano H, et al. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res 2009; 69: 13742.
  • 46
    Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, Nadin A, Smith AL, Stevenson G, Castro JL. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry 2000; 39: 8698704.
  • 47
    Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demthylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 1037.
  • 48
    Ou JN, Torrisani J, Unterberger A, Provencal N, Shikimi K, Karimi M, Ekstrom TJ, Szyf M. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 2007; 73: 1297307.
  • 49
    Milutinovic S, D'Alessio AC, Detich N, Szyf M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 2007; 28: 56071.